We understand the similarities between NNZ-2566 and NNZ-2591 but it is understanding the differences which will create alternative therapeutic pathways. It appears that NNZ-2591 may have a more direct effect on synaptic signalling.
Neurons do not connect with each other but communicate through a junction called a synapse. The junction is what Professor Mike Snape - http://vimeo.com/71532531 - might call the 'twitter space' where there are glia-neuron interactions, namely microglia and astrocyte.
There is a growing level of excitement about the MOA for NNZ-2591. The US Army is "characterising the impact of the drug on the restoration of synaptic function". Neuren have commenced testing NNZ-2591 in a mouse model of MS which is characterised in part by abnormal functioning of microglia.
Although the reasons are not yet fully understood, it does appear that NNZ-2591 is quite distinct from NNZ-2566. The results from the testing of NNZ-2591 in a mouse model for MS are eagerly anticipated.
biggest competitor to nnz-2566
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.18 |
Change
-0.430(3.16%) |
Mkt cap ! $1.684B | |||
| Open | High | Low | Value | Volume |
| $13.64 | $13.67 | $13.18 | $8.868M | 666.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 5233 | $13.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.24 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 09/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |